ID   NU-DUL-1
AC   CVCL_1877
SY   NUDUL-1; NUDUL1
DR   BTO; BTO_0006480
DR   CLO; CLO_0037051
DR   EFO; EFO_0006700
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-2969
DR   BioSample; SAMN03473485
DR   BioSample; SAMN10988580
DR   cancercelllines; CVCL_1877
DR   Cell_Model_Passport; SIDM00443
DR   ChEMBL-Cells; CHEMBL4523589
DR   ChEMBL-Targets; CHEMBL4523592
DR   Cosmic; 1629936
DR   Cosmic-CLP; 1330982
DR   DepMap; ACH-000287
DR   DSMZ; ACC-579
DR   DSMZCellDive; ACC-579
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   GDSC; 1330982
DR   GEO; GSM887460
DR   GEO; GSM888540
DR   GEO; GSM1035320
DR   GEO; GSM1670286
DR   IARC_TP53; 28303
DR   LiGeA; CCLE_504
DR   LINCS_LDP; LCL-1132
DR   PharmacoDB; NUDUL1_1171_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1877
DR   PubChem_Cell_line; CVCL_1877
DR   Wikidata; Q54931149
RX   PubMed=2581902;
RX   PubMed=19278952;
RX   PubMed=22460905;
RX   PubMed=23699601;
RX   PubMed=25355872;
RX   PubMed=25485619;
RX   PubMed=25960936;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=30285677;
RX   PubMed=30629668;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   Doubling time: ~30-36 hours (DSMZ=ACC-579).
CC   HLA typing: A*24:02,02:01; B*49:01,49:01; C*07:01,07:01; DQA1*05:01,05:01; DQB1*03:01,03:01; DRB1*12:01,03:02 (PubMed=25960936).
CC   HLA typing: A*24:02,24:02; B*49:01,49:01; C*07:01,07:01 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Asp119Asn (c.355G>A); ClinVar=VCV000040460; Zygosity=Heterozygous (Cosmic-CLP=1330982; DepMap=ACH-000287).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Val143Met (c.427G>A); ClinVar=VCV000142657; Zygosity=Heterozygous (Cosmic-CLP=1330982; DepMap=ACH-000287).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (Cosmic-CLP=1330982; DepMap=ACH-000287).
CC   Omics: Genomics; DNA methylation analysis.
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Genomics; Whole genome sequencing.
CC   Omics: Phenotyping; Drug screening.
CC   Omics: Proteomics; Quantitative.
CC   Omics: Transcriptomics; Microarray.
CC   Omics: Transcriptomics; miRNA profiling; Microarray.
CC   Omics: Transcriptomics; RNAseq virome analysis.
CC   Omics: Transcriptomics; RNAseq.
CC   Omics: Variations; Array-based CGH.
CC   Omics: Variations; CNV analysis.
CC   Omics: Variations; SNP array analysis.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=1.39%; East Asian, South=0.48%; South Asian=1.36%; European, North=63.99%; European, South=32.78% (PubMed=30894373).
CC   Derived from site: In situ; Cerebrospinal fluid; UBERON=UBERON_0001359.
ST   Source(s): ATCC=CRL-2969; Cosmic-CLP=1330982; DSMZ=ACC-579
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 8,13
ST   D16S539: 11,13
ST   D18S51: 13,14
ST   D19S433: 14,15
ST   D21S11: 28,32.2
ST   D2S1338: 24,25
ST   D3S1358: 14,16
ST   D5S818: 12,14
ST   D7S820: 11,13
ST   D8S1179: 13
ST   FGA: 22
ST   Penta D: 9,13
ST   Penta E: 10,13
ST   TH01: 9,9.3
ST   TPOX: 8
ST   vWA: 16,17
DI   NCIt; C36081; Diffuse large B-cell lymphoma activated B-cell type
DI   ORDO; Orphanet_544; Diffuse large B-cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   43Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 41
//
RX   PubMed=2581902; DOI=10.1002/ijc.2910350509;
RA   Epstein A.L., Variakojis D., Berger C.S., Kaiser-McCaw Hecht B.;
RT   "Use of novel chemical supplements in the establishment of three human
RT   malignant lymphoma cell lines (NU-DHL-1, NU-DUL-1, and NU-AMB-1) with
RT   chromosome 14 translocations.";
RL   Int. J. Cancer 35:619-627(1985).
//
RX   PubMed=19278952; DOI=10.1182/blood-2009-01-202028; PMCID=PMC3401058;
RA   Li C., Kim S.-W., Rai D., Bolla A.R., Adhvaryu S., Kinney M.C.,
RA   Robetorye R.S., Aguiar R.C.T.;
RT   "Copy number abnormalities, MYC activity, and the genetic fingerprint
RT   of normal B cells mechanistically define the microRNA profile of
RT   diffuse large B-cell lymphoma.";
RL   Blood 113:6681-6690(2009).
//
RX   PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23699601; DOI=10.1182/blood-2013-02-483727; PMCID=PMC3744992;
RA   Morin R.D., Mungall K., Pleasance E.D., Mungall A.J., Goya R.,
RA   Huff R.D., Scott D.W., Ding J.-R., Roth A., Chiu R., Corbett R.D.,
RA   Chan F.C., Mendez-Lago M., Trinh D.L., Bolger-Munro M., Taylor G.,
RA   Hadj Khodabakhshi A., Ben-Neriah S., Pon J., Meissner B., Woolcock B.W.,
RA   Farnoud N., Rogic S., Lim E.L., Johnson N.A., Shah S.P., Jones S.J.M.,
RA   Steidl C., Holt R.A., Birol I., Moore R., Connors J.M., Gascoyne R.D.,
RA   Marra M.A.;
RT   "Mutational and structural analysis of diffuse large B-cell lymphoma
RT   using whole-genome sequencing.";
RL   Blood 122:1256-1265(2013).
//
RX   PubMed=25355872; DOI=10.1128/JVI.02570-14; PMCID=PMC4301145;
RA   Cao S.-B., Strong M.J., Wang X., Moss W.N., Concha M., Lin Z.,
RA   O'Grady T., Baddoo M., Fewell C., Renne R., Flemington E.K.;
RT   "High-throughput RNA sequencing-based virome analysis of 50 lymphoma
RT   cell lines from the Cancer Cell Line Encyclopedia project.";
RL   J. Virol. 89:713-729(2015).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893; PMCID=PMC4355981;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5; PMCID=PMC6167786;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C.,
RA   Yang H.H., Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940.1-940.13(2018).
//
RX   PubMed=30629668; DOI=10.1371/journal.pone.0210404; PMCID=PMC6328144;
RA   Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.;
RT   "Screening human cell lines for viral infections applying RNA-Seq data
RT   analysis.";
RL   PLoS ONE 14:e0210404.1-e0210404.22(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//